What are the pros and cons of using organoids?
Dr Shona Lang investigates the advantages and disadvantages of using organoids within R&D, highlighting the most important questions to ask before using these models.
List view / Grid view
Articles
Uniting humans and data: the role of AI in genomics
AI has applications in many areas of research, including genomics. Slavé Petrovski of AstraZeneca reveals how AI is used in the study of the human genome and how it may evolve in the future.
Beyond the phenotype: using AI to better understand disease
Claus Bendtsen at AstraZeneca reveals how AI can be used to improve our understanding of disease, to help identify the causes of conditions and aid in drug discovery.
Applying AI language translation to the creation of new pharmaceuticals
Designing new drug molecules is crucial to R&D. Dr Sam Genway suggests that one way to improve and speed up this process is using AI inspired by language translation.
Five newest developments for imaging in drug research
Imaging methods are used by scientists to identify therapeutic targets and improve drug efficacy. This article lists five of the latest developments for imaging techniques.
Encouraging drug discovery and therapeutic targets for dementia
A review has been published by experts in neurodegeneration research, detailing six ways to improve dementia research. This article investigates one of these suggestions, focusing on how we can improve drug target identification.
Five latest developments for models
The use of models is a key feature of preclinical studies and in recent months there have been several new advancements in this area. This article investigates five of the latest developments.
Discovering new routes to cancer drug discovery with neutrons
From the world’s flagship neutron science facility, Institut Laue-Langevin (ILL), Matthew Blakeley shares insights into how they are harnessing the power of neutrons to aid their search for new cancer treatments.
Artificial intelligence in the world of drug discovery
Charlotte Walker-Osborn, a Partner and Head of Technology Sector (International) at global law-firm Eversheds Sutherland and a legal expert in technology law, explains some of the challenges and potential future of artificial intelligence (AI) in the field of drug discovery.
High-content imaging: challenges of the 3D world
The potential of three-dimensional cell culture models is now well-recognised by scientists; however, there are still some challenges. Margaritha Mysior and Jeremy Simpson address some of the common challenges of working with spheroids and organoid models – including how they are developed and how to obtain high-resolution, high-content images and…
Stem-cell technologies in immunotherapy
This article outlines the exciting developments that are taking place with immunotherapies and demonstrates how stem-cell technologies are proliferating the paradigm shift in how we tackle cancer treatment.
Using stem cells to study the effects of cannabis on neuronal development
Thanks to new developments with induced pluripotent stem cells enabling generation of human neurons, scientists can more precisely analyse the effects that chemicals have on human cells. This article describes research into the effects of cannabis on neuronal development and implications of its legalisation in Canada.
Image-based characterisation of cancer biotherapeutics
Scientists from LifeArc, an independent medical research charity in the UK, explain how they’re using the latest imaging technologies to progress drug discovery campaigns and identify the most promising candidates for antibody-based therapies.
Compound and fragment screening by native mass spectrometry
Native mass spectrometry has the potential to be a fast, simple, highly sensitive and automatable technique for compound screening in drug design and discovery. In this article, Rod Chalk and Nicola Burgess-Brown discuss the key attributes of native mass spectrometry and reasons why it is not yet widely employed.
Screening and beyond in drug discovery
Progressing drug discovery projects to a stage that attracts commercial interest is a challenging endeavour, evidenced by the fact that only a small proportion of drug discovery projects are successfully progressed to such a stage. A major cause of this is the lack of comprehensive profiling of compounds prior to…